米国のがん造影剤市場規模、シェア、動向分析レポート：タイプ別、モダリティ別、用途別、セグメント別予測、2024～2030年

米国のがん造影剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国のがん造影剤市場は2030年までに15億3,000万米ドルに達すると予測され、2024年から2030年までのCAGRは11.7％で拡大すると予測されています。

主要市場プレイヤ間の連携やパートナーシップの増加、政府および民間部門の研究開発投資の増加、画像診断におけるAIの統合が造影剤の能力を高めています。従って、これらの要因が米国がん造影剤市場の成長を後押ししています。

新製品の投入はメーカー間の競争を活性化させ、イノベーションを促進し、価格を引き下げ、最終的には患者とヘルスケアプロバイダーの両方の選択肢を増やすことになります。市場全体が拡大する可能性は、安全性の向上、標的特異性の強化、特徴的な画像特性を提供する新規造影剤の製造にかかっています。これにより、診断と治療の両方に新たな道が開かれます。例えば、GEヘルスケアは2023年4月、クラリスカン（ガドテリック酸）とピクソスキャン（ガドブトロール）という2つの最高級大環状分子をMRI薬剤の顧客基盤に導入し、造影剤の幅を広げました。業界の主要企業は、製品ポートフォリオを拡大することで新製品を市場に投入し、研究開発の強化に取り組んでおり、これが市場成長の原動力となっています。

さらに、ヘルスケア予算の増加は、がんの早期発見や高度な診断ツールへのアクセス向上を促進する公衆衛生イニシアチブを促進することが多いです。こうした取り組みにより、造影画像の重要性に対する認識が高まり、対応する造影剤への需要が高まっています。ヘルスケア予算の増加は新規参入者を惹きつけ、既存の利害関係者が市場で競争する動機付けとなります。このダイナミックな動きはイノベーションを刺激し、価格競合を助長し、最終的には医療従事者と患者の双方にとって幅広い選択肢をもたらします。このような取り組みが、市場拡大の有利な機会を生み出しています。

米国のがん造影剤市場レポート・ハイライト

• ヨード系造影剤は、医療画像診断の増加により、2023年に39.5%のシェアを占め、タイプ別セグメントを支配しました。
• 放射性薬剤セグメントは予測期間中に最も速いCAGRで成長すると予測されます。
• 核医学イメージング分野は、2023年に38.2％の最大市場シェアを占め、ヘルスケア専門家の正確な診断を可能にする体内の内部構造と機能の詳細で正確な画像を提供する能力により、予測期間中に最も速い成長を示すと予測されています。
• 座りがちなライフスタイル、喫煙率の増加、大気汚染の増加が、米国におけるがん患者の有病率増加の一因となっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国のがん造影剤市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場機会分析
  • 市場課題の分析
• 米国のがん造影剤市場：規制の枠組みと基準とコンプライアンス
• 米国のがん造影剤市場：償還シナリオ
• 米国のがん造影剤市場：分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 米国のがん造影剤市場：種類の推定・動向分析

• タイプ市場シェア、2023年および2030年
• セグメントダッシュボード
• 米国のがん造影剤市場：タイプ別展望

第5章 米国のがん造影剤市場：モダリティの推定・動向分析

• モダリティ市場シェア、2023年と2030年
• セグメントダッシュボード
• 米国のがん造影剤市場の見通し：モダリティ別

第6章 米国のがん造影剤市場：用途の推定・動向分析

• 用途市場シェア、2023年と2030年
• セグメントダッシュボード
• 米国のがん造影剤市場の見通し：用途別

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
• ベンダー情勢
  • List of key distributors and channel partners
  • Key customers
  • Key company market share analysis, 2023
  • Bayer AG
  • Lantheus
  • Bracco
  • Guerbet
  • Trivitron Healthcare
  • Cardinal Health
  • Telix Pharmaceuticals Limited
  • GE HealthCare
  • IMAX Diagnostic Imaging
  • Nano Therapeutics Pvt. Ltd.

List of Tables

• Table 1 List of abbreviation
• Table 2 U.S. cancer contrast media market, by type, 2018 - 2030 (USD Million)
• Table 3 U.S. cancer contrast media market, by modality, 2018 - 2030 (USD Million)
• Table 4 U.S. cancer contrast media market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in U.S.
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. cancer contrast media market: market outlook
• Fig. 10 U.S. cancer contrast media competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. cancer contrast media market driver impact
• Fig. 16 U.S. cancer contrast media market restraint impact
• Fig. 17 U.S. cancer contrast media market strategic initiatives analysis
• Fig. 18 U.S. cancer contrast media market: Type movement analysis
• Fig. 19 U.S. cancer contrast media market: Type outlook and key takeaways
• Fig. 20 Gadolinium-based contrast media market estimates and forecast, 2018 - 2030
• Fig. 21 Iodinated contrast media estimates and forecast, 2018 - 2030
• Fig. 22 Radioactive agents market estimates and forecast, 2018 - 2030
• Fig. 23 Others estimates and forecast, 2018 - 2030
• Fig. 24 U.S. cancer contrast media Market: Modality movement Analysis
• Fig. 25 U.S. cancer contrast media market: Modality outlook and key takeaways
• Fig. 26 Nuclear imaging market estimates and forecasts, 2018 - 2030
• Fig. 27 CT scans market estimates and forecasts, 2018 - 2030
• Fig. 28 Mammography market estimates and forecasts, 2018 - 2030
• Fig. 29 MRI scans market estimates and forecasts, 2018 - 2030
• Fig. 30 Ultrasound market estimates and forecasts, 2018 - 2030
• Fig. 31 U.S. cancer contrast media market: Application movement analysis
• Fig. 32 U.S. cancer contrast media market: Application outlook and key takeaways
• Fig. 33 Colorectal cancer market estimates and forecasts, 2018 - 2030
• Fig. 34 Bladder cancer market estimates and forecasts, 2018 - 2030
• Fig. 35 Breast cancer market estimates and forecasts, 2018 - 2030
• Fig. 36 Lung cancer market estimates and forecasts, 2018 - 2030
• Fig. 37 Prostate cancer market estimates and forecasts, 2018 - 2030
• Fig. 38 Other market estimates and forecasts, 2018 - 2030
• Fig. 39 Market share of key market players - U.S. cancer contrast media market
• Fig. 40 Key company categorization
• Fig. 41 Company market positioning
• Fig. 42 Key company market share analysis, 2023
• Fig. 43 Strategic framework

U.S. Cancer Contrast Media Market Growth & Trends:

The U.S. cancer contrast media market is anticipated to reach USD 1.53 billion by 2030 and is anticipated to expand at a CAGR of 11.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing collaboration and partnerships among key market players, coupled with growing government and private sector R&D investments, alongside the integration of AI in diagnostic imaging enhance the capabilities of contrast media. Thus, these factors collectively propel the growth of U.S. cancer contrast media market.

Introducing new products can ignite positive competition among manufacturers, fostering innovation, lowering prices, and ultimately enhancing choices for both patients and healthcare providers. The potential for expanding the overall market depends upon the manufacturing of novel contrast agents that offer heightened safety, enhanced target specificity, or distinctive imaging properties. This opens up new pathways for both diagnosis and treatment. For instance, in April 2023 , GE Healthcare has broadened its range of contrast media by introducing two premier macrocyclic molecules, namely Clariscan (gadoteric acid) and Pixxoscan (gadobutrol), to its customer base for MRI agents. The industry key players are involved in enhancing R&D by introducing novel products to the market by expanding their product portfolio, which drives market growth.

Moreover, increased funding in healthcare budgets often facilitates public health initiatives promoting early cancer detection and enhanced accessibility to advanced diagnostic tools. These initiatives enhance awareness of the importance of contrast-enhanced imaging, consequently fueling demand for corresponding contrast media. The growth in healthcare budgets attracts new players and motivates existing stakeholders to compete in the market. This dynamic stimulates innovation, fosters price competitiveness, and ultimately leads to a broader range of options for both healthcare providers and patients. Such initiatives create a lucrative opportunity for market expansion.

U.S. Cancer Contrast Media Market Report Highlights:

• Iodinated contrast media dominated the type segment with a share of 39.5% in 2023 owing to the increasing medical imaging procedures.
• The radioactive agents segment is expected to grow at the fastest CAGR over the forecast period.
• The nuclear imaging segment held the largest market share of 38.2% in 2023 and is anticipated to witness fastest growth over the forecast period owing to its ability to provide detailed and accurate images of internal structures and functions within the body which allows healthcare professionals for precise diagnosis.
• Sedentary lifestyle, increasing incidences of smoking and rising air pollution are contributing to the growing prevalence of cancer cases in U.S.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Modality
  • 1.2.3. Application
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in U.S.
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Modality outlook
  • 2.2.3. Application outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Cancer Contrast Media Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing number of clinical studies
    • 3.2.1.2. Rising cancer cases
    • 3.2.1.3. Technological advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Side effects and adverse reactions related to contrast agents
    • 3.2.2.2. Presence of alternative imaging options
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Increasing demand for medical imaging
  • 3.2.4. Market challenges analysis
    • 3.2.4.1. Shortage of contrast media due to supply chain disruptions
• 3.3. U.S. Cancer Contrast Media Market: Regulatory Framework and Standards & Compliances
• 3.4. U.S. Cancer Contrast Media Market: Reimbursement Scenario
• 3.5. U.S. Cancer Contrast Media Market Analysis Tools
  • 3.5.1. Industry Analysis - Porter's Five Forces
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis
    • 3.5.2.1. Political landscape
    • 3.5.2.2. Technological landscape
    • 3.5.2.3. Economic landscape

Chapter 4. U.S. Cancer Contrast Media Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. Cancer Contrast Media Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Gadolinium-based Contrast Media
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Iodinated Contrast Media
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Radioactive Agents
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Cancer Contrast Media Market: Modality Estimates & Trend Analysis

• 5.1. Modality Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. U.S. Cancer Contrast Media Market by Modality Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Nuclear Imaging
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. CT scans
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Mammography
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. MRI scans
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Ultrasound
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Cancer Contrast Media Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. U.S. Cancer Contrast Media Market by Application Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Breast Cancer
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Bladder Cancer
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Colorectal Cancer
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Lung Cancer
    • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Prostate Cancer
    • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Bayer AG
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Lantheus
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Bracco
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Guerbet
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Trivitron Healthcare
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Cardinal Health
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Telix Pharmaceuticals Limited
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. GE HealthCare
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. IMAX Diagnostic Imaging
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Nano Therapeutics Pvt. Ltd.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives